血清骨硬化蛋白、成纤维生长因子23水平与老年2型糖尿病患者骨代谢异常及骨质疏松风险的关系
孙敬波 , 袁红亮 , 刘冰 , 郑新颖 , 季洪良
中国现代医学杂志 ›› 2026, Vol. 36 ›› Issue (17) : 82 -88.
血清骨硬化蛋白、成纤维生长因子23水平与老年2型糖尿病患者骨代谢异常及骨质疏松风险的关系
Association of serum sclerostin and fibroblast growth factor 23 levels with bone metabolic abnormalities and osteoporosis risk in elderly patients with type 2 diabetes mellitus
目的 探讨血清骨硬化蛋白(SOST)及成纤维生长因子23(FGF23)水平与老年2型糖尿病患者骨代谢异常及骨质疏松风险的关系,并评估其在骨质疏松风险预测中的临床价值。 方法 选取2023年1月—2025年1月北京中医药大学东方医院秦皇岛医院就诊的老年2型糖尿病患者96例,依据双能X射线吸收法(DEXA)检测所得骨密度(BMD)数值,按照相关诊断标准将研究对象划分为骨量正常组32例、骨量减少组34例及骨质疏松组30例。比较3组血清SOST、FGF23及骨代谢相关指标水平差异,分析其与BMD及骨形成标志物的相关性,并采用受试者工作特征(ROC)曲线评估SOST、FGF23单项及联合预测骨质疏松风险的效能。 结果 骨量正常组、骨量减少组和骨质疏松组年龄、糖尿病病程和糖化血红蛋白(HbA1c)水平比较,差异均有统计学意义(P <0.05);年龄和糖尿病病程两两比较均有统计学意义(P <0.05),随骨密度降低呈逐渐升高趋势。骨量正常组、骨量减少组和骨质疏松组SOST水平和FGF23水平比较,差异均有统计学意义(P <0.05);SOST和FGF23水平两两比较均有统计学意义(P <0.05),SOST水平逐级降低,FGF23水平逐级升高。骨量正常组、骨量减少组和骨质疏松组腰椎L2~4 BMD、股骨颈BMD、骨钙素(BGP)及骨碱性磷酸酶(BALP)水平比较,差异均有统计学意义(P <0.05);各指标两两比较差异均有统计学意义(P <0.05)。腰椎L2~4 BMD、股骨颈BMD、BGP及BALP水平均随骨量下降呈逐级降低趋势。Pearson相关性分析结果显示:血清SOST水平与腰椎L2~4 BMD、股骨颈BMD、BGP、BALP均呈正相关(r =0.457、0.456、0.348、0.327,P <0.05),血清FGF23水平与腰椎L2~4 BMD、股骨颈BMD、BGP、BALP均呈负相关(r =-0.469、-0.335、-0.305、-0.292,P <0.05)。年龄增加[O^R =1.324(95% CI:1.018,1.722)]、糖尿病病程延长[O^R =1.657(95% CI:1.125,2.442)]、HbA1c升高[O^R =6.565(95% CI:1.503,28.677)]、FGF23升高[O^R =1.082(95% CI:1.016,1.153)]均为老年2型糖尿病患者发生骨质疏松的危险因素,SOST升高[O^R =0.318(95% CI:0.109,0.925)]为其保护因素(均P <0.05)。SOST与FGF23联合检测诊断骨质疏松的曲线下面积为0.927(95% CI:0.868,0.986),敏感性为90.0%,特异性为81.2%,约登指数为0.712。 结论 血清SOST降低、FGF23升高与老年2型糖尿病患者骨密度下降及骨代谢异常密切相关,二者联合检测对骨质疏松风险评估具有较高预测价值。
Objective To explore the relationships of circulating sclerostin (SOST) and fibroblast growth factor 23 (FGF23) with alterations in bone metabolism among older individuals with type 2 diabetes, and to assess their utility in identifying patients at high risk for osteoporosis. Methods Ninety-six elderly patients with type 2 diabetes admitted to our hospital from January 2023 to January 2025 were included. According to bone mineral density values obtained using dual-energy X-ray absorptiometry, subjects were stratified into three subgroups: normal bone mass (n = 32), osteopenia (n = 34), and osteoporosis (n = 30). Serum concentrations of SOST and FGF23, together with bone metabolic indices, were compared across groups. Associations between these biomarkers and bone mineral density at different skeletal sites as well as markers of bone formation were evaluated. Receiver operating characteristic curve analysis was applied to determine the discriminative performance of SOST, FGF23, and their combined model for osteoporosis. Results There were statistically significant differences in age, duration of diabetes, and glycated hemoglobin (HbA1c) levels among the normal bone mass group, osteopenia group, and osteoporosis group (P < 0.05). Age and duration of diabetes showed significant pairwise differences among the three groups (P < 0.05), with gradually increasing trends as bone density decreased. Significant differences were observed in serum SOST and FGF23 levels among the three groups (P < 0.05). Pairwise comparisons also showed statistically significant differences (P < 0.05), with SOST levels decreasing progressively and FGF23 levels increasing progressively. Significant differences were also found in lumbar L2-4 BMD, femoral neck BMD, bone gla protein (BGP), and bone alkaline phosphatase (BALP) levels among the three groups (P < 0.05), and all indicators showed progressively decreasing trends with declining bone mass. Pearson correlation analysis demonstrated that serum SOST levels were positively correlated with lumbar L2-4 BMD and femoral neck BMD (r = 0.457 and 0.456, respectively; P < 0.001), and were also positively correlated with BGP and BALP levels (r = 0.348 and 0.327, respectively; P < 0.05). Serum FGF23 levels were negatively correlated with lumbar L2-4 BMD and femoral neck BMD (r = -0.469 and -0.335, respectively; P < 0.05), and were also negatively correlated with BGP and BALP levels (r = -0.305 and -0.292, respectively; P < 0.05). Increased age [O^R = 1.324 (95% CI: 1.018, 1.722) ], longer duration of diabetes [O^R = 1.657 (95% CI: 1.125, 2.442) ], elevated HbA1c [O^R = 6.565 (95% CI: 1.503, 28.677) ], and increased FGF23 [O^R = 1.082 (95% CI: 1.016, 1.153) ] were identified as risk factors for osteoporosis in elderly patients with T2DM, whereas elevated SOST [O^R = 0.318 (95% CI: 0.109, 0.925) ] was identified as a protective factor. The area under the curve (AUC) for the combined detection of SOST and FGF23 in diagnosing osteoporosis was 0.927 (95% CI: 0.868, 0.986), with a sensitivity of 90.0%, specificity of 81.2%, and Youden index of 0.712. Conclusion Decreased serum SOST and elevated FGF23 levels are closely associated with reduced bone mineral density and bone metabolic abnormalities in elderly patients with T2DM. Combined assessment of these two biomarkers provides substantial value for osteoporosis risk stratification.
| [1] |
孟莹莹, 赵明利, 石颖欣, 2型糖尿病老年患者并发骨质疏松症的影响因素及其与UAER、CCr、25(OH)D3的关系[J]. 中华保健医学杂志, 2025, 27(3): 434-437. |
| [2] |
李秀秀, 班东日, 黎依技, 老年2型糖尿病合并骨质疏松患者骨折预测模型构建[J]. 中国骨质疏松杂志, 2025, 31(7): 979-985. |
| [3] |
李昕逸, 陆守荣, 宋承雅, 老年2型糖尿病合并骨质疏松症危险因素的研究进展[J]. 中国临床保健杂志, 2024, 27(6): 849-854. |
| [4] |
王盟盟, 张磊, 周凤云, 双层光谱CT、QCT及DXA在骨质疏松诊断中的精确性与效能比较[J]. CT理论与应用研究, 2024, 33(6): 717-724. |
| [5] |
孙鹏, 张国华, 陈超斌, 血清Irisin、SOST、H2S与膝骨关节炎合并骨质疏松症患者骨密度、骨代谢标志物的相关性及其预测价值[J]. 现代生物医学进展, 2024, 24(10): 1980-1984. |
| [6] |
袁丽, 游敏. 老年2型糖尿病合并骨质疏松患者血清IL-34、LCN2、FGF23水平及临床意义[J]. 检验医学与临床, 2024, 21(24): 3601-3604. |
| [7] |
Jiao Z X, Chai H, Wang S D, et al. SOST gene suppression stimulates osteocyte Wnt/β-catenin signaling to prevent bone resorption and attenuates particle-induced osteolysis[J]. J Mol Med (Berl), 2023, 101(5): 607-620. |
| [8] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. |
| [9] |
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691. |
| [10] |
Sharma P, Sharma R K, Gaur K. Understanding the impact of diabetes on bone health: a clinical review[J]. Metabol Open, 2024, 24: 100330. |
| [11] |
孙思露, 陶思敏, 席小燕, 老年营养风险指数对老年2型糖尿病患者骨质疏松的预测价值分析[J]. 河北医学, 2023, 29(8): 1372-1377. |
| [12] |
赵波, 许丙义, 徐海斌, 老年2型糖尿病患者血清CYR61、caveolin-1水平与骨质疏松症的关系[J]. 广东医学, 2023, 44(2): 224-228. |
| [13] |
Jiang J J, Zhao C Y, Han T T, et al. Advanced glycation end products, bone health, and diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2022, 130(10): 671-677. |
| [14] |
李俊伟, 秦凡, 罗宇茜. 老年脊柱退行性改变伴骨质疏松症患者血尿酸、脂代谢及维生素D的变化与预测价值[J]. 川北医学院学报, 2025, 40(7): 905-908. |
| [15] |
余开心, 朱飞宇, 谢亚羽, 杭州萧山地区老年人骨质疏松及血清维生素D水平的现况研究[J]. 中国医学前沿杂志(电子版), 2023, 15(10): 41-48. |
| [16] |
Zhang Z H, Jia X Y, Fang J Y, et al. Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis[J]. J Cell Mol Med, 2020, 24(7): 4233-4244. |
| [17] |
Liu D, Yang H Y, Liao Q R, et al. Circulating FGF-23 is associated with increased risk of osteoporosis and fractures in hemodialysis patients: a prospective observational study[J]. Int J Clin Pract, 2024, 2024(1): 1070492. |
| [18] |
Adhish M, Manjubala I. An in-silico approach to the potential modulatory effect of taurine on sclerostin (SOST) and its probable role during osteoporosis[J]. J Biomol Struct Dyn, 2024, 42(17): 9002-9017. |
| [19] |
Wu K F, Ren W Y, Xu B E, et al. GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression[J]. J Orthop Surg Res, 2026, 21(1): 95. |
| [20] |
Traechslin C, Sewing L, Baumann S, et al. Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus[J]. J Clin Transl Endocrinol, 2025, 40: 100393. |
| [21] |
Martínez-Montoro J I, GarcíA-Fontana B, GarcíA-Fontana C, et al. Evaluation of quality and bone microstructure alterations in patients with type 2 diabetes: a narrative review[J]. J Clin Med, 2022, 11(8): 2206. |
| [22] |
Sirikul W, Siri-Angkul N, Chattipakorn N, et al. Fibroblast growth factor 23 and osteoporosis: evidence from bench to bedside[J]. Int J Mol Sci, 2022, 23(5): 2500. |
| [23] |
van der Vaart A, Eelderink C, van Beek A P, et al. Fibroblast growth factor 23, glucose homeostasis, and incident diabetes: findings of 2 cohort studies[J]. J Clin Endocrinol Metab, 2023, 108(10): e971-e978. |
| [24] |
Vilaca T, Eastell R. Efficacy of osteoporosis medications in patients with type 2 diabetes[J]. Curr Osteoporos Rep, 2024, 22(1): 1-10. |
2026年度河北省医学科学研究课题计划(20261141)
/
| 〈 |
|
〉 |